Israel Englander’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Israel Englander’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,000	Closed	-$1.2M	–	7465
2022 Q4	$1.2M	Buy	+200,000	New	+$1.09M	﹤0.01%	3985

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Israel Englander's CTIC Position: Q2 2023 in Review

Israel Englander sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 866,152 shares — an estimated $3.64M sold.

Israel Englander first reported a position in CTIC in Q2 2013 and held it in 30 quarters. The position peaked at $28.6M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Israel Englander reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Israel Englander sold 866,152 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $3.64M.
Israel Englander first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 30 quarters.
Israel Englander's CTI BioPharma Corp. (DE) Common Stock position peaked at $28.6M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.